NTRK Gene Fusion Detection in Atypical Spitz Tumors
- PMID: 34830218
- PMCID: PMC8619835
- DOI: 10.3390/ijms222212332
NTRK Gene Fusion Detection in Atypical Spitz Tumors
Abstract
Atypical Spitz tumors (AST) deviate from stereotypical Spitz nevi for one or more atypical features and are now regarded as an intermediate category of melanocytic tumors with uncertain malignant potential. Activating NTRK1/NTRK3 fusions elicit oncogenic events in Spitz lesions and are targetable with kinase inhibitors. However, their prevalence among ASTs and the optimal approach for their detection is yet to be determined. A series of 180 ASTs were screened with pan-TRK immunohistochemistry and the presence of NTRK fusions was confirmed using FISH, two different RNA-based NGS panels for solid tumors, and a specific real time RT-PCR panel. Overall, 26 ASTs showed pan-TRK immunostaining. NTRK1 fusions were detected in 15 of these cases showing cytoplasmic immunoreaction, whereas NTRK3 was detected in one case showing nuclear immunoreaction. Molecular tests resulted all positive in only two ASTs (included the NTRK3 translocated), RNA-based NGS and real time RT-PCR were both positive in three cases, and FISH and real time RT-PCR in another two cases. In seven ASTs NTRK1 fusions were detected only by FISH and in two cases only by real time RT-PCR. The frequency of NTRK fusions in ASTs is 9%, with a clear prevalence of NTRK1 compared to NTRK3 alterations. Pan-TRK immunohistochemistry is an excellent screening test. Confirmation of NTRK fusions may require the use of different molecular techniques.
Keywords: NTRK; NTRK1; NTRK3; atypical spitz tumor; pan-TRK.
Conflict of interest statement
DM has received honoraria for professional services and consultancy for Bayer HealthCare Pharmaceuticals Inc. (Whippany, NJ, USA). The remaining authors declare that they have no conflict of interest.
Figures



Similar articles
-
Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.Cancer Genet. 2022 Apr;262-263:47-52. doi: 10.1016/j.cancergen.2021.12.010. Epub 2022 Jan 2. Cancer Genet. 2022. PMID: 35007853
-
Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.Pathology. 2022 Feb;54(1):55-62. doi: 10.1016/j.pathol.2021.05.100. Epub 2021 Sep 10. Pathology. 2022. PMID: 34518039
-
Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing.Endocr Pathol. 2020 Dec;31(4):348-358. doi: 10.1007/s12022-020-09648-9. Epub 2020 Sep 3. Endocr Pathol. 2020. PMID: 32880785
-
Identifying patients with NTRK fusion cancer.Ann Oncol. 2019 Nov;30 Suppl 8:viii16-viii22. doi: 10.1093/annonc/mdz384. Epub 2019 Dec 24. Ann Oncol. 2019. PMID: 32223934 Review.
-
The role of gene fusions in melanocytic neoplasms.J Cutan Pathol. 2019 Nov;46(11):878-887. doi: 10.1111/cup.13521. Epub 2019 Jun 20. J Cutan Pathol. 2019. PMID: 31152596 Review.
Cited by
-
TRK Protein Expression in Merkel Cell Carcinoma Is Not Caused by NTRK Fusions.Int J Mol Sci. 2022 Dec 6;23(23):15366. doi: 10.3390/ijms232315366. Int J Mol Sci. 2022. PMID: 36499693 Free PMC article.
-
Spitz Tumors and Melanoma in the Genomic Age: A Retrospective Look at Ackerman's Conundrum.Cancers (Basel). 2023 Dec 14;15(24):5834. doi: 10.3390/cancers15245834. Cancers (Basel). 2023. PMID: 38136379 Free PMC article. Review.
-
The Spectrum of Spitz Melanocytic Lesions: From Morphologic Diagnosis to Molecular Classification.Front Oncol. 2022 Jun 7;12:889223. doi: 10.3389/fonc.2022.889223. eCollection 2022. Front Oncol. 2022. PMID: 35747831 Free PMC article. Review.
-
Cutaneous Melanomas: A Single Center Experience on the Usage of Immunohistochemistry Applied for the Diagnosis.Int J Mol Sci. 2022 May 25;23(11):5911. doi: 10.3390/ijms23115911. Int J Mol Sci. 2022. PMID: 35682589 Free PMC article. Review.
-
NTRK gene aberrations in triple-negative breast cancer: detection challenges using IHC, FISH, RT-PCR, and NGS.J Pathol Clin Res. 2023 Sep;9(5):367-377. doi: 10.1002/cjp2.324. Epub 2023 May 4. J Pathol Clin Res. 2023. PMID: 37143440 Free PMC article.
References
-
- Gerami P., Busam K., Cochran A., Cook M.G., Duncan L.M., Elder D.E., Fullen D.R., Guitart J., LeBoit P.E., Mihm M.C., Jr., et al. Histomorphologic assessment and interobserver diagnostic reproducibility of atypical spitzoid melanocytic neoplasms with long-term follow-up. Am. J. Surg. Pathol. 2014;38:934–940. doi: 10.1097/PAS.0000000000000198. - DOI - PubMed
-
- Cerroni L., Barnhill R., Elder D., Gottlieb G., Heenan P., Kutzner H., LeBoit P.E., Mihm M., Jr., Rosai J., Kerl H. Melanocytic tumors of uncertain malignant potential: Results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. Am. J. Surg. Pathol. 2010;34:314–326. doi: 10.1097/PAS.0b013e3181cf7fa0. - DOI - PubMed